Figure 2

Hepatitis B virus DNA and hepatitis B e antigen levels during nucleos(t)ide analog therapy. Viral load rebound presented in month 104 and in month 133. Combination therapy with entecavir 1mg plus adefovir 10mg daily was applied to inhibit viral load in month 106. Multidrug resistance mutations, namely rtL180M, rtM204V, rtA181T 30%/V 20%/wt 50% and rt T184G 40%/wt 60%, were identified in month 133. Thus, combination treatment with entecavir 0.5mg plus tenofovir 300mg daily was immediately selected in this time point. Viral load gradually decreased, and creatinine clearance correspondingly increased.